PRAME is a target expressed in more than 50 cancers, including melanoma, lung, ovarian, breast, and endometrial cancer, among many others. Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. To do so safely and effectively requires deep expertise in immunology, drug development and beyond.
Immatics has the broadest PRAME franchise with the most indications and therapeutic modalities.
Clinical trials
Immatics is evaluating its targeted PRAME cell therapies and bispecific product candidates and actively enrolling patients in ongoing clinical trials.
Press releases
Follow our progress as we advance PRAME therapies from lab to clinic and beyond.
Today, we announced updated Phase 1a dose escalation data from both product candidates in our TCR Bispecifics (TCER®) pipeline, IMA402 PRAME Bispecific
Earlier this week, the Immatics team attended the ESMO - European Society for Medical Oncology congress.
Last week, our Houston Immatics team laced up their sneakers and hit the pavement at the Chord Energy Houston Corporate 5K!